Taking a Look at the Operational Data for Nektar Therapeutics (NKTR)

Nektar Therapeutics (NASDAQ:NKTR) is one of the more popular stocks investors are adding into their watchlist. Now trading with a market value of 12.94B, the company has a mix of catalysts and obstacles that spring from the nature of its operations. In light of the many issues surrounding this company, we thought it was a good time to take a close look at the numbers in order to form a realistic perspective on the fundamental picture for this stock.

Nektar Therapeutics (NASDAQ:NKTR) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For NKTR, the company currently has 37.97 million of cash on the books, which is offset by 2.48 million in current liabilities. The trend over time is important to note. In this case, the company’s debt has been falling. The company also has 582.06 million in total assets, balanced by 497.89 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

Nektar Therapeutics (NKTR) saw 92.14 million in free cash flow last quarter, representing a quarterly net change in cash of 21.82 million. Perhaps most importantly where cash movements are concerned, the company saw about 93.08 million in net operating cash flow.

Nektar Therapeutics (NASDAQ:NKTR) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 152.93 million in total revenues. That represents a quarterly year/year change in revenues of 3.21 in sequential terms, the NKTR saw sales decline by 3.42.

But what about the bottom line? After all, that’s what really matters in the end. Nektar Therapeutics (NKTR) is intriguing when broken down to its core data. The cost of selling goods last quarter was 5.67 million, yielding a gross basic income of 147.25 million. For shareholders, given the total diluted outstanding shares of 162.64 million, this means overall earnings per share of 0.37. Note, this compares with a consensus analyst forecast of -0.35 in earnings per share for its next fiscal quarterly report.

Is Nektar Therapeutics (NASDAQ:NKTR) Valuation Attractive

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about -1.27 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 9,999. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Nektar Therapeutics.

Previous ArticleNext Article

Related Post

Argos Therapeutics, Inc. (ARGS) and AmpliPhi Biosc... Argos Therapeutics, Inc. (NASDAQ:ARGS) shares are down more than -96.37% this year and recently decreased -1.06% to settle at $0.18. AmpliPhi Bioscien...
AMAG Pharmaceuticals, Inc. (AMAG): Checking the Op... AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) is one the of the active stocks and its unusual movement is rasing eyebrows among traders. Now trading with a...
Why You Should Want To Trade Finisar Corporation (... Finisar Corporation (NASDAQ:FNSR) trade is getting exciting but lets take a deeper look whether it is as good a moment. Now trading with a market valu...
How Does the Fundamental Picture Look for STMicroe... STMicroelectronics N.V. (NYSE:STM)'s interesting series of developments are underway around the US stock market these days. Now trading with a market ...
How Does the Fundamental Picture Look for United T... United Technologies Corporation (NYSE:UTX) is an interesting stock at present. Now trading with a market value of 101.91B, the company has a mix of ca...